A Colton-supported NYU study published in Science Translational Medicine has identified impaired regulatory T cells as a key driver of Sjögren's disease — and found a promising existing drug as a potential therapy.
A Colton-supported NYU study published in Science Immunology has discovered that the immune checkpoint protein PD-1 functions as a dimer — a finding that could transform drug design for both cancer and autoimmune disease.
NYU Langone researchers have linked lupus flare-ups to blooms of a specific gut bacterium, opening a potential path to probiotic and dietary treatments less toxic than current immunosuppressive therapies.
NYU Langone's Colton-backed Division of Rheumatology is taking a leading role in the NIH's $58 million AMP AIM program, driving research into lupus, psoriatic disease, Sjögren's disease, and the microbiome.
Colton-supported NYU researchers have found that autoantibodies can physically inactivate a key enzyme in over half of lupus nephritis patients — a non-genetic mechanism that could serve as a future biomarker and therapeutic target.
NYU Langone's Colton Center has funded seven new autoimmune pilot projects for 2019 — targeting myasthenia gravis, rheumatoid arthritis, and lupus — while earlier grants advance toward clinical diagnostics and therapies.
NYU Langone's Colton Center for Autoimmunity profiles its cross-disciplinary pilot research program — connecting researchers across rheumatology, immunology, genetics, and neuroimmunology to accelerate autoimmune disease breakthroughs.
